Navigation Links
Oclaro Reports Positive Adjusted EBITDA in First Post-Merger Quarter
Date:7/23/2009

SAN JOSE, Calif., July 23 /PRNewswire-FirstCall/ -- Oclaro, Inc. (Nasdaq: OCLR), a leading provider of optical components, modules and subsystems, today announced the financial results for its fourth fiscal quarter and fiscal year ended June 27, 2009. Oclaro, Inc. was formed April 27, 2009 from the combination of Bookham, Inc., renamed Oclaro, Inc. on that date, and Avanex Corporation.

"Being positive Adjusted EBITDA in our first quarter together is an important milestone for Oclaro. Our integration is going smoothly, our synergies are on track and we believe our customers are pleased with the deal. These results are a visual indicator of the progress taking place behind the scenes and with customers," said Alain Couder, CEO of Oclaro, Inc. "Times continue to be challenging, and we expect only modest revenue growth in the remainder of calendar 2009. Over the upcoming quarters we will continue to focus to advance the profitability of Oclaro towards our ultimate operating model targets."

Highlights: Fourth Fiscal Quarter 2009

  • GAAP revenues were $66.9 million for the quarter ended June 27, 2009 compared to $41.2 million in the quarter ended March 28, 2009. GAAP gross margin was 25% for the quarter ended June 27, 2009, compared to 21% in the quarter ended March 28, 2009.
    • GAAP revenues exclude New Focus revenues of $5.1 million and $5.8 million for the quarters ended June 27, 2009 and March 28, 2009, respectively, as New Focus results of operation are disclosed as discontinued operations as a result of the transfer of our New Focus business to Newport Corporation in exchange for their Spectra-Physics laser diode business and $3.0 million in cash in a transaction that closed July 4, 2009.
  • Non-GAAP revenues were $72.0 million for the quarter ended June 27, 2009, which included two months of revenues of Avanex Corporation, compared to $47.0 million in the third quarter of fiscal 2009, which included no Avanex revenues. Non-GAAP revenues include the revenues of New Focus, which is treated as a discontinued operation in our GAAP financial statements.
    • A reconciliation table of non-GAAP measures to the most comparable GAAP measures is included in the financial tables section of this release and further discussion of these measures is also included later in this release.
    • Non-GAAP revenues for the quarter ended June 27, 2009 would have been $78.1 million including all three months of Avanex's revenues.
  • Non-GAAP gross margin was 25% for the quarter ended June 27, 2009, compared to 23% in the quarter ended March 28, 2009. Non-GAAP gross margin excludes $0.3 million of stock compensation in each of the quarters ended June 27, 2009 and March 28, 2009. Non-GAAP gross margin benefited from non-recurring items, in particular the inclusion of Avanex results for two out of the three months in the quarter, and would have otherwise been approximately 21% on a recurring basis.
  • Adjusted EBITDA was positive $0.7 million for the quarter ended June 27, 2009, compared to negative $0.7 million in the quarter ended March 28, 2009.
  • Net loss for the quarter ended June 27, 2009 was $14.6 million, which included $5.2 million of restructuring and related costs and $1.1 million of stock-based compensation, compared to a net loss of $13.3 million in the quarter ended March 28, 2009, which included $0.1 million of restructuring and related costs and $1.1 million of stock-based compensation.
  • Cash, cash equivalents, restricted cash and short-term investments were $58.0 million as of June 27, 2009.
  • On April 27, 2009, we announced a three year extension of our $25.0 million line of credit facility through August, 2011. We have no amounts drawn under this line, and have no debt outstanding.

"While the merger with Avanex in our fourth fiscal quarter was a highlight for the year, we are also proud of having improved our annual gross margin and annual adjusted EBITDA, in spite of the current economic downturn that began in September 2008," said Couder. "We will continue to execute and expect the related results to deliver enhanced shareholder value."

Highlights: Fiscal Year 2009

  • GAAP Revenues were $210.9 million for the twelve months ended June 27, 2009, which includes two months of Avanex revenues, compared to $202.7 million for the twelve months ended June 28, 2008.
  • GAAP Gross margin was 22% for the twelve months ended June 27, 2009, compared to 20% for the twelve months ended June 28, 2008.
  • Non-GAAP Revenues were $235.8 million for the twelve months ended June 27, 2009, which includes two months of Avanex revenues, compared to $235.5 million for the twelve months ended June 28, 2008.
  • Adjusted EBITDA was negative $1.0 million for the twelve months ended June 27, 2009, compared to negative $4.0 million for the twelve months ended June 28, 2008.
  • Non-GAAP net loss for the twelve months ended June 27, 2009 was $3.1 million, compared to $14.0 million for the twelve months ended June 28, 2008.

First Quarter Fiscal 2010 Outlook

The results of Oclaro, Inc. for the first quarter of fiscal 2010, which ends September 26, 2009, are expected to be as follows:

  • Revenues in the range of $76 million to $84 million.
  • Non-GAAP gross margin between 19% and 23%. This guidance reflects approximately 2% to 3% of temporary gross margin dilution from our acquisition of the Spectra-Physics laser diode business in exchange for our New Focus business, as we will be incurring additional costs while we transition related fabrication activities to Europe in the next 6 to 12 months.
  • Adjusted EBITDA of negative $6.0 million to breakeven.

The foregoing guidance is based on current expectations. These statements are forward looking, and actual results may differ materially. Please see the Safe Harbor Statement in this earnings release for a description of certain important risk factors that could cause actual results to differ, and refer to Oclaro, Inc's (formerly Bookham .Inc.) most recent annual and quarterly reports on file with the Securities and Exchange Commission (SEC) for a more complete description of the risks. Furthermore, our outlook excludes items that may be required by GAAP, including, but not limited to, restructuring and related costs, acquisition or disposal related costs, expenses or income from certain legal actions, settlements and related costs outside our normal course of business, impairments of other long-lived assets, extraordinary items, as well as the expensing of stock options and restricted stock grants under SFAS 123R.

Conference Call

Oclaro will report financial results for the fourth quarter of fiscal 2009 today at 2:00 p.m. PT/5:00 p.m. ET. To listen to the live conference call, please dial (480) 629-9643. A replay of the conference call will be available through July 30, 2009. To access the replay, dial (303) 590-3030. The conference code for the replay is 4116120. A webcast of this call will be available in the investors section of Oclaro's website at www.oclaro.com.

About Oclaro

Oclaro, Inc., with headquarters in San Jose, California, is a tier 1 provider of high performance optical components, modules and subsystems to the telecommunications market, and is one of the largest providers to metro and long haul network applications. The company, formed on April, 27, 2009, following the combination of Bookham, Inc. and Avanex Corporation, leverages proprietary core technologies and vertically integrated product development to provide its customers with cost-effective and innovative optical devices, modules and subsystems. The company serves a broad customer base, combining in-house and outsourced manufacturing to maximize flexibility and drive improved gross margin. Its photonic technologies also serve selected high growth markets, including industrial, defense, life sciences, medical and scientific, with diversification providing both significant revenue streams and strategic technological advantage. Oclaro is a global company, with cutting edge chip fabrication facilities in the UK, Switzerland and Italy, and in Tucson, Arizona during the transition of related activities to Europe, and manufacturing sites in the US, Thailand and China.

Oclaro and all other Oclaro product names and slogans are trademarks or registered trademarks of Oclaro, Inc. in the USA or other countries. Spectra-Physics is a registered trademark of Newport Corporation.

Safe Harbor Statement

This press release and the statements made by management contain statements about management's future expectations, plans or prospects of Oclaro, Inc. and its business, and the assumptions underlying these statements, constitute forward-looking statements for the purposes of the safe harbor provisions of The Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements concerning (i) financial targets, including financial targets related to gross margin; research and development expenses; sales, general and administrative expenses and non-GAAP operating margin, (ii) financial guidance for the fiscal quarter ending September 26, 2009, including guidance regarding revenue, non-GAAP gross margin and adjusted EBITDA and revenue outlook for the remainder of 2009, (iii) the impact of the acquisition of Avanex Corporation and the Spectra-Physics asset swap on the combined entity's gross margin, (iv) sources for improvement of gross margin and operating expenses, including supply chain synergies, optimizing mix of product offerings, transition to higher margin product offerings, benefits of combined R&D and sales organizations and single public company costs, (v) the expected first year financial opportunities, including becoming profitable in 12 months, obtaining quarterly operating cash breakeven (non-GAAP) by end of first year, expected synergies per quarter by end of the fourth full quarter after close of the merger with Avanex Corporation and restructuring costs, (vi) opportunities to grow in adjacent markets and (vii) statements containing the words "target," "believe," "plan," "anticipate," "expect," "estimate," "will," "should," "ongoing," and similar expressions. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including the impact of continued uncertainty in world financial markets and the resulting reduction in demand for our products, the future performance of Oclaro, Inc. following the closing of the merger with Avanex Corporation and the Spectra-Physics asset swap, the inability to realize the expected benefits and synergies as a result of the of the merger with Avanex Corporation and the Spectra-Physics asset swap, increased costs related to downsizing and compliance with regulatory compliance in connection with such downsizing, the lack of availability of credit or opportunity for equity based financing, as well as the factors described in Oclaro's most recent registration statement on Form S-4, most recent annual report on Form 10-K, most recent quarterly reports on Form 10-Q and other documents we periodically file with the SEC. The forward-looking statements included in this announcement represent Oclaro's view as of the date of this presentation. Oclaro anticipates that subsequent events and developments may cause Oclaro's views and expectations to change. However, Oclaro specifically disclaims any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this release.

Non-GAAP Financial Measures

The Company provides certain supplemental non-GAAP financial measures to its investor as a complement to the most comparable GAAP measures.

The Company believes that providing these non-GAAP measures to its investors, in addition to corresponding income statement measures, provides investors the benefit of viewing the Company's performance using the same financial metrics that the management team uses in making many key decisions and understanding how the core business and its results of operations may look in the future. The Company further believes that providing this information allows the Company's investors greater transparency and a better understanding of the Company's core financial performance. Additionally, each non-GAAP measure has historically been presented by the Company as a complement to its most comparable GAAP measure, and the Company believes that the continuation of this practice increases the consistency and comparability of the Company's earnings releases. The non-GAAP adjustments, and the basis for excluding them, are discussed further below.

Non-GAAP financial measures are not in accordance with, or an alternative for, generally accepted accounting principles in the United States of America. Non-GAAP measures should not be considered in isolation from or as a substitute for financial information presented in accordance with generally accepted accounting principles, and may be different from non-GAAP measures used by other companies. The GAAP measure most directly comparable to non-GAAP revenues is revenues. The GAAP measure most directly comparable to non-GAAP net income/loss is net income/loss. The GAAP measure most directly comparable to Adjusted EBITDA is net income/loss. The GAAP measure most directly comparable to non-GAAP gross margin rate is gross margin rate. An explanation and reconciliation of each of these non-GAAP financial measures to GAAP information is set forth below.

Non-GAAP Revenues

Non-GAAP revenues include the revenues of New Focus, which is treated as a discontinued operation in our GAAP financial statements. Management uses this non-GAAP measure to evaluate its performance relative to its previously established financial targets. Specifically, the Company previously reported New Focus in its revenues and provided guidance for the fourth quarter of fiscal 2009 which included the New Focus business. The Company believes providing non-GAAP revenues to its investors, in addition to corresponding income statement measures, allows investors to evaluate the Company's results of operations compared to its previous financial results and previously provided guidance for the fourth quarter of fiscal 2009.

Non-GAAP Net Income/Loss

Non-GAAP net income/loss is calculated as net income/loss excluding the impact of restructuring and severance costs, non-cash compensation related to stock and options granted to employees and directors, income taxes, impairment charges and certain other one-time charges and credits specifically identified in the non-GAAP reconciliation schedules set forth below. The Company uses non-GAAP net income/loss in evaluating the Company's historical and prospective operating financial performance, as well as its operating performance relative to its competitors. Specifically, management uses this non-GAAP measure to further understand the Company's "core operating performance." The Company believes its "core operating performance" represents the Company's on-going performance in the ordinary course of its operations. Accordingly, management excludes from "core operating performance" those items, such as impairment charges, income taxes, restructuring and severance programs and costs relating to specific major projects which are non-recurring, expenses or income from certain legal actions, settlements and related costs, as well as non-cash compensation related to stock and options. Management does not believe these items, including recurring non-cash items, are reflective of the Company's ongoing operations and accordingly excludes those items from non-GAAP net income/loss.

Adjusted EBITDA

Adjusted EBITDA is calculated as net income/loss excluding the impact of taxes, net interest income/expense, depreciation and amortization, net foreign currency translation gains/losses, as well as restructuring and severance, impairment, non-cash compensation related to stock and options, expenses or income from certain legal actions, settlements and related costs outside our normal course of business, and certain other one-time charges and credits specifically identified in the non-GAAP reconciliation schedules set forth below. The Company uses Adjusted EBITDA in evaluating the Company's historical and prospective cash usage, as well as its cash usage relative to its competitors. Specifically, management uses this non-GAAP measure to further understand and analyze the cash used in/generated from the Company's core operations. The Company believes that by excluding these non-cash and non-recurring charges, more accurate expectations of its future cash needs can be assessed in addition to providing a better understanding of the actual cash used in or generated from core operations for the periods presented.

The Company further believes that providing this information allows the Company's investors greater transparency and a better understanding of the Company's core cash position.

Non-GAAP Gross Margin Rate

Non-GAAP gross margin rate is calculated as gross margin rate as determined in accordance with GAAP (gross profit as a percentage of revenues) excluding non-cash compensation related to stock and options specifically identified in the non-GAAP reconciliation schedules set forth below. The Company evaluates its performance using non-GAAP gross margin rate to assess the Company's historical and prospective operating financial performance, as well as its operating performance relative to its competitors. Specifically, management uses this non-GAAP measure to further understand the Company's "core operating performance." The Company believes its "core operating performance" represents the Company's on-going performance in the ordinary course of its operations. Accordingly, management excludes from "core operating performance" those items such as non-cash compensation related to stock and options; and certain other significant non-recurring one-time charges and credits specifically identified. Management does not believe these items, including recurring non-cash items, are reflective of the Company's ongoing operations and accordingly excludes those items from non-GAAP gross margin rate.

Non-GAAP Operating Loss

Non-GAAP operating loss is calculated as operating loss as determined in accordance with GAAP excluding the impact of amortization of intangible assets, restructuring and severance costs, non-cash compensation related to stock and options granted to employees and directors, impairment charges, and certain other one-time charges and credits specifically identified in the non-GAAP reconciliation schedules set forth below. The Company evaluates its performance using, among other things, non-GAAP operating loss in evaluating the Company's historical and prospective operating financial performance, as well as its operating performance relative to its competitors. Specifically, management uses this non-GAAP measure to further understand the Company's "core operating performance." The Company believes its "core operating performance" represents the Company's on-going performance in the ordinary course of its operations. Accordingly, management excludes from "core operating performance" those items such as restructuring and severance programs and costs relating to specific major projects which are non-recurring, expenses or income from certain legal actions, settlements and related costs outside our normal course of business, impairment charges, as well as non-cash compensation related to stock and options. Management does not believe these items are reflective of the Company's ongoing operations and accordingly excludes those items from non-GAAP operating loss.

Specific Notes on Certain Excluded Items

Certain Legal Actions, Settlement and Related Costs

In the second and third quarters of fiscal 2009, the Company recorded expenses of $0.3 million and $3.7 million, respectively, related to the settlement of outstanding litigation with JDS Uniphase Corporation on April 10, 2009. Of these amounts, $3.0 million is paid or payable to JDS Uniphase and $1.0 million relates to legal costs incurred by the Company related to this litigation. In the first quarter of fiscal 2009, the Company recorded a gain, net of costs incurred, related to the settlement of a legal action against a third party in connection with land sold by the Company in 2006, net of insurance recoveries, both of which are included in its GAAP statement of operations.

Goodwill and Intangibles Impairment

As part of the Company's preparation of its financial statements for the second quarter of fiscal 2009, the Company determined that the value of its goodwill was impaired. During the second fiscal quarter, there was a decline in the revenue forecasts for the optical components industry, with a corresponding reduction in the Company's market capitalization and revenue projections. These were some of the factors that triggered the impairment of goodwill. Based on the results of a preliminary evaluation, the Company recorded a non-cash impairment charge of $7.9 million in the second quarter of fiscal 2009. During the third quarter of fiscal 2009, the Company completed its full evaluation of the impairment analysis for goodwill, which indicated that the goodwill of $7.9 million was fully impaired. The impairment will not result in any current or future cash expenditures.

During the third quarter of fiscal 2009, in conjunction with the full evaluation of goodwill impairment, the Company also evaluated the fair value of certain intangible assets. Based on this testing, the Company recorded a non-cash impairment charge of $4.0 million in its third quarter statement of operations to recognize impairment of certain intangible assets.

                                   OCLARO, INC.
                       CONDENSED CONSOLIDATED BALANCE SHEETS
                             (unaudited, in thousands)

                       ASSETS                    June 27, 2009  June 28, 2008
                                                 -------------  -------------
    Current assets:
      Cash and cash equivalents                     $44,561        $32,863
      Short-term investments                          9,259         17,845
      Restricted cash                                 4,208          1,154
      Accounts receivable, net                       58,483         41,445
      Inventories                                    59,527         53,708
      Prepaid expenses and other
       current assets                                11,834          5,685
      Assets held for sale                           10,442         11,122
                                                     ------         ------
    Total current assets                            198,314        163,822
                                                    -------        -------
    Goodwill                                              -          7,881
    Other intangible assets, net                      1,951          7,829
    Property and equipment, net                      29,875         32,286
    Other non-current assets                          3,248            272
                                                      -----            ---
      Total assets                                 $233,388       $212,090
                                                   ========       ========

        LIABILITIES AND STOCKHOLDERS' EQUITY
    Current liabilities:
      Accounts payable                              $31,943        $19,053
      Accrued expenses and other liabilities         39,016         20,044
      Liabilities held for sale                       2,028          3,193
                                                      -----          -----
    Total current liabilities                        72,987         42,290
                                                     ------         ------
    Other long-term liabilities                       4,923          1,336
    Deferred gain on sale-leaseback                  15,088         19,402
                                                     ------         ------
    Total liabilities                                92,998         63,028
                                                     ------         ------
    Stockholders' equity:
      Common stock                                    1,862          1,007
      Additional paid-in capital                  1,199,358      1,163,598
      Accumulated other comprehensive
       income                                        30,905         44,036
      Accumulated deficit                        (1,091,735)    (1,059,579)
                                                 ----------     ----------
    Total stockholders' equity                      140,390        149,062
                                                    -------        -------
            Total liabilities and
             stockholders' equity                  $233,388       $212,090
                                                   ========       ========



                                         OCLARO, INC.
                       CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
                     (unaudited, in thousands, except per share amounts)

                          Three Months Ended   Twelve Months Ended
                          -------------------  --------------------
                          June 27,  March 28,  June 27,   June 28,
                            2009      2009       2009       2008
                          --------  ---------  ---------  ---------

    Revenues               $66,877    $41,241   $210,923   $202,663
    Cost of revenues        50,296     32,381    164,425    161,902
                            ------     ------    -------    -------
    Gross profit            16,581      8,860     46,498     40,761

    Operating expenses:
        Research and
         development         8,272      5,260     26,147     28,608
        Selling, general
         and administrative 10,659      7,601     34,899     40,948
        Amortization of
         intangible assets      58         54        487      3,510
        Restructuring and
         related costs       5,157         54      6,826      3,033
        Legal settlements        -      3,705      3,829     (2,882)
        Gain on sale of
         property and
         equipment              (4)       (16)       (12)    (2,562)
        Impairment of
         goodwill and
         other intangible
         assets                  -      1,252      9,133          -
                               ---      -----      -----        ---
    Total operating
     expenses               24,142     17,910     81,309     70,655
                            ------     ------     ------     ------

    Operating loss          (7,561)    (9,050)   (34,811)   (29,894)
    Other income
     (expense):
        Other income
         (expense)              15         (5)      (685)         -
        Interest income         53         78        575      1,261
        Interest
         expense              (110)      (109)      (543)      (682)
        Foreign
         currency
         translation
         gain (loss), net   (4,670)      (598)    11,094      6,059
                            ------       ----     ------      -----
    Total other income
     (expense)              (4,712)      (634)    10,441      6,638
                            ------       ----     ------      -----
    Loss from
     continuing
     operations before
     income taxes          (12,273)    (9,684)   (24,370)   (23,256)
    Income tax
     provision               1,406         19      1,399          5
                             -----        ---      -----        ---
    Loss from
     continuing
     operations            (13,679)    (9,703)   (25,769)   (23,261)
    Loss from
     discontinued
     operations,
    net of taxes              (928)    (3,578)    (6,387)      (179)
                              ----     ------     ------       ----
    Net loss              $(14,607)  $(13,281)  $(32,156)  $(23,440)
                          ========   ========   ========   ========

    Basic and diluted
     net loss per share:
        Net loss per
         share from
         continuing
         operations         $(0.09)    $(0.10)    $(0.22)    $(0.25)
        Net loss per
         share from
         discontinued
         operations              -      (0.04)     (0.06)         -
                                ---      -----      -----        ---
        Net loss per
         share              $(0.09)    $(0.13)    $(0.28)    $(0.25)
                            ======     ======     ======     ======
    Shares used in
     computing net loss
     per share:
        Basic and diluted  158,537     99,604    114,844     93,099


    Stock-based compensation
     included in the following:
      Cost of revenues         279        265      1,168      2,130
      Research and
       development             238        216        888      1,938
      Selling, general
       and administrative      525        490      2,017      4,266
      Loss from discontinued
       operations, net of tax   91         91        364        477
                               ---        ---        ---        ---
        Total                1,133      1,062      4,436      8,812
                             =====      =====      =====      =====



                                   OCLARO, INC.
     RECONCILIATION OF GAAP FINANCIAL MEASURES TO NON-GAAP FINANCIAL MEASURES
               (unaudited, in thousands, except per share amounts)

                               Three Months Ended    Twelve Months Ended
                               -------------------   --------------------
                              June 27,   March 28,   June 27,   June 28,
                                2009       2009        2009       2008
                              ---------  ----------  ---------  ---------
    Reconciliation of GAAP
     revenues to non-GAAP
     revenues:
      GAAP revenues             $66,877     $41,241   $210,923   $202,663
        Revenues from
         discontinued
         operations               5,148       5,751     24,829     32,828
                                  -----       -----     ------     ------
                                $72,025     $46,992   $235,752   $235,491
                                =======     =======   ========   ========

    Reconciliation of GAAP
     net loss to non-GAAP
     net income (loss) and
     adjusted EBITDA:
      GAAP net loss            $(14,607)   $(13,281)  $(32,156)  $(23,440)
        Stock-based
         compensation             1,133       1,062      4,436      8,812
        Restructuring and
         related costs:
          Continuing
           operations             5,157          54      6,826      3,033
          Discontinued
           operations               229           6        588        438
        Legal settlements             -       3,705      3,829     (2,882)
        Income tax provision:
          Continuing
           operations             1,406          19      1,399          5
          Discontinued
           operations                                       50
        Impairment of
         goodwill and other
         intangible assets:
          Continuing
           operations                 -       1,252      9,133          -
          Discontinued
           operations                 -       2,782      2,782          -
                                      -       -----      -----          -
      Non-GAAP net loss          (6,682)     (4,401)    (3,113)   (14,034)
                                 ------      ------     ------    -------
        Depreciation expense:
          Continuing
           operations             2,535       2,761     10,954     12,029
          Discontinued
           operations                66          88        308        201
        Amortization expense:
          Continuing
           operations                58          54        487      3,510
          Discontinued
           operations                 -         210        742      1,129
        Impairment of short-
         term investments             -           -        706          -
        Interest income
         (expense), net              57          39        (37)      (794)
        Foreign currency
         translation (gain)
         loss, net                4,667         599    (11,096)    (6,038)
                                  -----         ---    -------     ------
      Adjusted EBITDA              $701       $(650)   $(1,049)   $(3,997)
                                   ====       =====    =======    =======

      Non-GAAP net loss per
       share:
          Basic and diluted      $(0.04)     $(0.04)    $(0.03)    $(0.15)
    Shares used in computing
     Non-GAAP net loss per
     share:
          Basic and diluted     158,537      99,604    114,844     93,099



                                   OCLARO, INC.
     RECONCILIATION OF GAAP FINANCIAL MEASURES TO NON-GAAP FINANCIAL MEASURES
               (unaudited, in thousands, except per share amounts)

                                   Three Months Ended    Twelve Months Ended
                                   -------------------   --------------------
                                  June 27,   March 28,   June 27,   June 28,
                                    2009       2009        2009       2008
                                  ---------  ----------  ---------  ---------
    Reconciliation of GAAP gross
     margin rate to non-GAAP
     gross margin rate:
      GAAP gross profit:
          Continuing operations     $16,581      $8,860    $46,498    $40,761
          Discontinued operations    $1,410      $2,029     $7,716    $12,212
        Stock compensation included
         in cost of revenues:
          Continuing operations         279         265      1,168      2,130
          Discontinued operations        24          25        104        133
                                        ---         ---        ---        ---
      Non-GAAP gross profit         $17,991     $10,889    $54,214    $52,973
                                    =======     =======    =======    =======

      GAAP gross margin rate           24.8%       21.5%      22.0%      20.1%
      Non-GAAP gross margin rate       25.0%       23.2%      23.0%      22.5%

    Reconciliation of GAAP
     operating loss to non-GAAP
     operating loss:
      GAAP operating loss:
          Continuing operations     $(7,561)    $(9,050)  $(34,811)  $(29,894)
          Discontinued operations     $(977)    $(3,569)   $(6,390)     $(373)
        Stock-based compensation      1,133       1,062      4,436      8,812
        Restructuring and
         related costs:
          Continuing operations       5,157          54      6,826      3,033
          Discontinued operations       229           6        588        438
        Legal settlements                 -       3,705      3,829     (2,882)
        Amortization of
         intangible assets:
          Continuing operations          58          54        487      3,510
          Discontinued operations         -         210        742      1,129
        Impairment of goodwill and
         other intangible assets:
          Continuing operations           -       1,252      9,133          -
          Discontinued operations         -       2,782      2,782          -
                                        ---       -----      -----        ---
      Non-GAAP operating loss       $(1,961)    $(3,494)  $(12,378)  $(16,227)
                                    =======     =======   ========   ========




'/>"/>
SOURCE Oclaro, Inc.
Copyright©2009 PR Newswire.
All rights reserved


Related medicine news :

1. Oclaro Launches Eye-Safe High Power Laser Diodes at LASER 2009
2. Hard to Treat Diseases, Inc. (HTDS) Reports on Ribavirin Research as Potential Treatment for MS
3. Zimmer Holdings, Inc. Reports Second Quarter 2009 Financial Results
4. Wyeth Reports Earnings Results for the 2009 Second Quarter and First Half and Raises Full Year 2009 Guidance
5. Digirad Corporation Reports Second Quarter 2009 Financial Results
6. Affymetrix Reports Second Quarter 2009 Results
7. Exponent Reports Second Quarter 2009 Results
8. Endologix Reports 42% Second Quarter 2009 Revenue Growth
9. Universal Health Realty Income Trust Reports 2009 Second Quarter Financial Results
10. Lilly Reports Solid Second-Quarter 2009 Results, Raises EPS Guidance
11. Amylin Pharmaceuticals Reports Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... FL (PRWEB) , ... February 09, 2016 , ... ... innovative specialty pharmacies, announces today the continuation of the ‘Pay It Forward’ program ... each prescription referral received at our specialty pharmacy. , “Since our Pay ...
(Date:2/9/2016)... ... 2016 , ... On January 12, 2016 Paul McElwee, a CroppMetcalfe HVAC technician, ... furnace not producing any heat. Shortly after entering the home, Paul was able to ... dangerous levels of carbon monoxide into the home, at 2,000 parts per million in ...
(Date:2/9/2016)... ... February 09, 2016 , ... The Bon-Ton ... and Younkers department stores, announced it has raised $176,000 to benefit the Breast ... Comprehensive Cancer Center at the University of Iowa, The Lynn Sage Cancer Research ...
(Date:2/9/2016)... ... February 09, 2016 , ... ZipHearing.com ... access to affordable hearing aids , increase industry transparency, and promote awareness ... United States. , “For the average consumer, the hearing aid industry is esoteric ...
(Date:2/9/2016)... , ... February 09, 2016 , ... ... products, announced today the introduction of the newly designed, innovative shoulder wrap. ... better cold therapy coverage for the injured arm and shoulder to promote faster ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... Aesthetic Devices - Medical Devices Pipeline Assessment, ... "Aesthetic Devices - Medical Devices Pipeline Assessment, 2015" provides ... This report is prepared using data ... GlobalData,s team of industry experts. *Note: Certain sections ... on the availability and relevance of data in relation ...
(Date:2/8/2016)... FAIRFIELD, N.J. , Feb. 8, 2016  Otsuka ... today announced that they have entered into a licensing ... OPA-15406 in the U.S. and Puerto Rico ... is a topical, non-steroidal phosphodiesterase IV (PDE-4) inhibitor, a ... --> --> In a Phase II ...
(Date:2/8/2016)... , Feb. 8, 2016  Echo ... medical device company focused on non-invasive continuous ... announced today announced that it will host ... February 17, 2015 at 9:00 a.m. Eastern ... discuss its corporate strategy, advancements in its ...
Breaking Medicine Technology: